KR101523698B1 - 사람 암 줄기세포 - Google Patents

사람 암 줄기세포 Download PDF

Info

Publication number
KR101523698B1
KR101523698B1 KR1020097017268A KR20097017268A KR101523698B1 KR 101523698 B1 KR101523698 B1 KR 101523698B1 KR 1020097017268 A KR1020097017268 A KR 1020097017268A KR 20097017268 A KR20097017268 A KR 20097017268A KR 101523698 B1 KR101523698 B1 KR 101523698B1
Authority
KR
South Korea
Prior art keywords
stem cells
cells
cell
cancer stem
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097017268A
Other languages
English (en)
Korean (ko)
Other versions
KR20100033471A (ko
Inventor
제니 피. 마더
페넬로프 로버츠
Original Assignee
마크로제닉스 웨스트 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크로제닉스 웨스트 인코퍼레이티드 filed Critical 마크로제닉스 웨스트 인코퍼레이티드
Publication of KR20100033471A publication Critical patent/KR20100033471A/ko
Application granted granted Critical
Publication of KR101523698B1 publication Critical patent/KR101523698B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097017268A 2007-01-22 2008-01-22 사람 암 줄기세포 Expired - Fee Related KR101523698B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US88149707P 2007-01-22 2007-01-22
US60/881,497 2007-01-22
US90718007P 2007-03-23 2007-03-23
US60/907,180 2007-03-23
US92424707P 2007-05-04 2007-05-04
US60/924,247 2007-05-04
US95071407P 2007-07-19 2007-07-19
US60/950,714 2007-07-19
US97261307P 2007-09-14 2007-09-14
US60/972,613 2007-09-14
PCT/US2008/051730 WO2008091908A2 (en) 2007-01-22 2008-01-22 Human cancer stem cells

Publications (2)

Publication Number Publication Date
KR20100033471A KR20100033471A (ko) 2010-03-30
KR101523698B1 true KR101523698B1 (ko) 2015-05-29

Family

ID=39641454

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097017268A Expired - Fee Related KR101523698B1 (ko) 2007-01-22 2008-01-22 사람 암 줄기세포

Country Status (9)

Country Link
US (1) US8309354B2 (https=)
EP (1) EP2109668A4 (https=)
JP (1) JP2010516259A (https=)
KR (1) KR101523698B1 (https=)
CN (1) CN101855339A (https=)
AU (1) AU2008207945A1 (https=)
CA (1) CA2675521C (https=)
IL (1) IL199836A (https=)
WO (1) WO2008091908A2 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523698B1 (ko) 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포
CN102203290B (zh) 2008-10-27 2015-05-06 北海道公立大学法人札幌医科大学 肿瘤干细胞分子标记
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011078301A1 (ja) 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
EP2596119B8 (en) 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2611463A2 (en) 2010-09-03 2013-07-10 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
CA2810016A1 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
JP6230789B2 (ja) * 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
KR101182549B1 (ko) * 2010-12-16 2012-09-12 엘지이노텍 주식회사 3차원 입체 카메라 모듈
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
ES2586599T3 (es) * 2011-03-24 2016-10-17 The Rogosin Institute Ensayo para cribar compuestos que disminuyen selectivamente el número de células madre de cáncer
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6077997B2 (ja) * 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
US10247731B2 (en) 2012-02-22 2019-04-02 Verik Bio, Inc. System for immunotherapy targeting tumor propagation and progression
CA2865415C (en) 2012-02-24 2022-06-21 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
JP6090735B2 (ja) * 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
CA3223380A1 (en) * 2012-03-19 2013-09-26 Stemline Therapeutics, Inc. Methods for treating and monitoring the status of cancer
DK3536334T3 (da) 2012-05-16 2021-09-13 Stemline Therapeutics Inc Cancer stamcelle målrettede cancer vacciner
WO2014165101A1 (en) * 2013-03-13 2014-10-09 California Stem Cell, Inc. Individualized high purity colon carcinoma stem cells, methods and use of the same
BR112015019909A2 (pt) 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
TWI659210B (zh) * 2013-08-12 2019-05-11 Minerva Biotechnologies Corporation 加強腫瘤生長的方法
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
AU2014312310A1 (en) 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Novel SEZ6 modulators and methods of use
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
PE20160993A1 (es) 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
CN106537148B (zh) * 2014-06-25 2019-10-11 泰尔哈绍梅尔医学研究基础设施和服务有限公司 癌症干细胞的鉴定及其用于诊断和治疗的用途
US20170191034A1 (en) * 2014-09-04 2017-07-06 Agency For Science Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP2018510844A (ja) * 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
JP6161828B2 (ja) * 2015-04-20 2017-07-12 国立大学法人 岡山大学 がんの非ヒトモデル動物及びその作製方法、がん幹細胞及びその製造方法
EP3208331A1 (en) * 2016-02-17 2017-08-23 PromoCell bioscience alive GmbH Biomedizinische Produkte Chemically defined medium for the culture of cancer stem cell (csc) containing cell populations
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
EP3454864A4 (en) 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Novel anti-bmpr1b antibodies and methods of use
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
GB201700952D0 (en) * 2017-01-19 2017-03-08 Univ Cape Town In vitro propagation of primary cancer cells
CN107904206A (zh) * 2017-11-17 2018-04-13 张家港澳洋医院有限公司 一种脂多糖诱导肿瘤细胞生成肿瘤干细胞的用途和方法
AU2019284405B2 (en) * 2018-06-13 2025-08-21 Genex Health Co.,Ltd Colorectal cancer solid tumour primary cell and colorectal cancer ascitic fluid primary tumour cell culturing method, and matching reagent
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
CN109652377B (zh) * 2019-01-15 2023-03-28 广州医科大学 一种肺癌干细胞的制备方法及应用
WO2021046186A1 (en) * 2019-09-04 2021-03-11 Vcell Therapeutics, Inc. Vaccine for treatment of cancer and method of making by stress reprogramming
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
CN113069547B (zh) * 2021-04-16 2023-01-24 同济大学附属第一妇婴保健院 Bap1作为肿瘤治疗靶点在制备预防或治疗肿瘤药物中的应用
CN113444690A (zh) * 2021-07-29 2021-09-28 大连大学 一种基于三维培养体系的肿瘤细胞耐照射模型的建立方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050136066A1 (en) 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2003032814A2 (en) 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
JP2005522483A (ja) 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
MXPA04012664A (es) 2002-06-19 2005-08-15 Raven Biotechnologies Inc Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo.
MXPA06003028A (es) 2003-09-18 2006-06-23 Raven Biotechnologies Inc Medios de cultivo de celulas.
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
KR101295139B1 (ko) 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
ITRM20040438A1 (it) 2004-09-15 2004-12-15 Univ Palermo Metodo per la purificazione e l'amplificazione di cellule staminali tumorali.
CA3218940A1 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
US7687242B2 (en) 2005-01-12 2010-03-30 Raven Biotechnologies, Inc. KID31 and antibodies that bind thereto
WO2006084078A2 (en) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
AU2006210589B2 (en) 2005-02-02 2011-12-08 Macrogenics West, Inc. ADAM-9 modulators
EP1846455A4 (en) 2005-02-03 2010-02-17 Raven Biotechnologies Inc ANTIBODY TO THE ONKOSTATIN M RECEPTOR
BRPI0607450A2 (pt) 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
US20090012024A1 (en) 2005-07-26 2009-01-08 Procure Therapeutics Limited Stem Cell Markers
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
KR101523698B1 (ko) 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dalerba, P. et al., Annu. Rev. Med., 2007, vol.58, pp.267-284 (2006.9.26. 온라인 공개) *

Also Published As

Publication number Publication date
CN101855339A (zh) 2010-10-06
IL199836A0 (en) 2010-04-15
US8309354B2 (en) 2012-11-13
CA2675521C (en) 2016-04-26
EP2109668A2 (en) 2009-10-21
JP2010516259A (ja) 2010-05-20
IL199836A (en) 2014-02-27
KR20100033471A (ko) 2010-03-30
AU2008207945A1 (en) 2008-07-31
WO2008091908A3 (en) 2009-12-30
CA2675521A1 (en) 2008-07-31
WO2008091908A2 (en) 2008-07-31
US20080175870A1 (en) 2008-07-24
EP2109668A4 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
KR101523698B1 (ko) 사람 암 줄기세포
ES2432744T3 (es) Células del tejido adiposo extramedular y sus aplicaciones en la reconstitución del tejido cardiaco
JP6630074B2 (ja) 新規に単離された細胞の治療組成物の操作および送達
KR20200003913A (ko) 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
KR102944529B1 (ko) 항-pd-1 항체에 불응성인 nsclc 환자의 치료
WO2019060336A1 (en) IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS
JP2021522860A (ja) キメラ抗原受容体で修飾されたγδ Ｔ細胞を生産する方法
TW202208617A (zh) 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
KR20210136050A (ko) 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
TW202208616A (zh) 改良之腫瘤反應性ｔ細胞的選擇
KR20160093654A (ko) 종양을 치료하는 방법
TW202239415A (zh) 腫瘤浸潤性淋巴球療法與ｃｔｌａ－４及ｐｄ－１抑制劑組合之治療
WO2024183144A1 (zh) 一种多重基因编辑的通用型巨噬细胞及在制备抗肿瘤药物中的应用
TW202300014A (zh) 腫瘤儲存及細胞培養組成物
KR102032384B1 (ko) 제대혈 단핵세포에서의 자연살해세포의 제조 방법
US20230149523A1 (en) Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
CN117480246A (zh) 用于t细胞共培养物效力测定和配合细胞疗法产品使用的方法和组合物
JP7733640B2 (ja) 不死化された筋芽細胞株及びその使用
KR102957749B1 (ko) 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
HK40100827A (zh) 肿瘤储存及细胞培养组合物
WO2025096638A2 (en) Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
JP2025537155A (ja) Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
CN116829156A (zh) 使用肿瘤浸润性淋巴细胞疗法与ctla-4及pd-1抑制剂组合的治疗
WO2023086803A1 (en) Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
HK40100826A (zh) 使用肿瘤浸润性淋巴细胞疗法与ctla-4及pd-1抑制剂组合的治疗

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180522

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180522